These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 8549381)

  • 61. Sparfloxacin and other new fluoroquinolones.
    Richard P; Gutmann L
    J Antimicrob Chemother; 1992 Dec; 30(6):739-44. PubMed ID: 1337749
    [No Abstract]   [Full Text] [Related]  

  • 62. Antimicrobial activity, pharmacokinetics and clinical studies of balofloxacin (Q-35) in obstetrics and gynaecology.
    Cho N; Miyakawa Z; Kimura T; Shimizu A; Notake Y; Kunii K
    Drugs; 1995; 49 Suppl 2():391-2. PubMed ID: 8549373
    [No Abstract]   [Full Text] [Related]  

  • 63. Parameters of Mycoplasma pneumoniae infection in Syrian hamsters.
    Barile MF; Chandler DK; Yoshida H; Grabowski MW; Harasawa R; Razin S
    Infect Immun; 1988 Sep; 56(9):2443-9. PubMed ID: 3137169
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Antimycoplasmal activity of dimethylphenols in a tracheal explant culture system.
    Agee CC; Engelhardt JA; Gabridge MG
    Antimicrob Agents Chemother; 1980 Aug; 18(2):243-8. PubMed ID: 6778378
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Study design, methodology and statistical analyses in the clinical development of sparfloxacin.
    Genevois E; Lelouer V; Vercken JB; Caillon R
    J Antimicrob Chemother; 1996 May; 37 Suppl A():65-72. PubMed ID: 8737126
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Use of newer quinolones for the treatment of intraabdominal infections: focus on clinafloxacin.
    Nord CE
    Infection; 1999; 27(3):166-72. PubMed ID: 10378126
    [No Abstract]   [Full Text] [Related]  

  • 67. Characterization and pathogenicity of hemolysis mutants of Mycoplasma pneumoniae.
    Yayoshi M; Araake M; Hayatsu E; Kawakubo Y; Yoshioka M
    Microbiol Immunol; 1984; 28(3):303-10. PubMed ID: 6429484
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Atypical pneumonia and the Armed Forces Epidemiological Board.
    Denny FW
    J Infect Dis; 1981 Mar; 143(3):305-16. PubMed ID: 6785362
    [No Abstract]   [Full Text] [Related]  

  • 69. [Comparative study of mono- and mixed Mycoplasma-pneumococcus infection in hamsters].
    Semenenko TA; Gotvianskaia TP; Vasil'eva VI
    Zh Mikrobiol Epidemiol Immunobiol; 1981 Dec; (12):62-6. PubMed ID: 7036609
    [No Abstract]   [Full Text] [Related]  

  • 70. Reacquisition of specific proteins confers virulence in Mycoplasma pneumoniae.
    Krause DC; Leith DK; Baseman JB
    Infect Immun; 1983 Feb; 39(2):830-6. PubMed ID: 6403461
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Antimycobacterial quinolones: a comparative analysis of structure-activity and structure-cytotoxicity relationships.
    Klopman G; Fercu D; Li JY; Rosenkranz HS; Jacobs MR
    Res Microbiol; 1996; 147(1-2):86-96. PubMed ID: 8761728
    [No Abstract]   [Full Text] [Related]  

  • 72. Sparfloxacin in the treatment of leprosy patients.
    Ishii N; Sugita Y; Sato I; Nakajima H
    Int J Dermatol; 1997 Aug; 36(8):619-21. PubMed ID: 9329897
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Implications of mycoplasma contamination in Plasmodium falciparum cultures and methods for its detection and eradication.
    Rowe JA; Scragg IG; Kwiatkowski D; Ferguson DJ; Carucci DJ; Newbold CI
    Mol Biochem Parasitol; 1998 Apr; 92(1):177-80. PubMed ID: 9574920
    [No Abstract]   [Full Text] [Related]  

  • 74. Growth factors for Mycoplasma pneumoniae in yeast and tissue extracts.
    Rylance HJ; Marr W; Malcolm MG; Stewart SM; Marmion BP
    J Appl Bacteriol; 1979 Oct; 47(2):341-5. PubMed ID: 120357
    [No Abstract]   [Full Text] [Related]  

  • 75. 4th International Symposium on New Quinolones. Proceedings. Munich, Germany, August 27-29, 1992.
    Drugs; 1993; 45 Suppl 3():1-475. PubMed ID: 7689438
    [No Abstract]   [Full Text] [Related]  

  • 76. Experimental and clinical studies of sparfloxacin in Mycoplasma pneumoniae infection.
    Kaku M; Ishida K; Kohno S; Koga H; Hara K; Usui T
    Drugs; 1995; 49 Suppl 2():412-3. PubMed ID: 8549381
    [No Abstract]   [Full Text] [Related]  

  • 77. In vitro and in vivo activities of sparfloxacin against Mycoplasma pneumoniae.
    Kaku M; Ishida K; Irifune K; Mizukane R; Takemura H; Yoshida R; Tanaka H; Usui T; Tomono K; Suyama N
    Antimicrob Agents Chemother; 1994 Apr; 38(4):738-41. PubMed ID: 8031039
    [TBL] [Abstract][Full Text] [Related]  

  • 78. In vitro and in vivo activities of Q-35, a new fluoroquinolone, against Mycoplasma pneumoniae.
    Gohara Y; Arai S; Akashi A; Kuwano K; Tseng CC; Matsubara S; Matumoto M; Furudera T
    Antimicrob Agents Chemother; 1993 Sep; 37(9):1826-30. PubMed ID: 8239590
    [TBL] [Abstract][Full Text] [Related]  

  • 79. In vitro and in vivo efficacies of T-3811ME (BMS-284756) against Mycoplasma pneumoniae.
    Takahata M; Shimakura M; Hori R; Kizawa K; Todo Y; Minami S; Watanabe Y; Narita H
    Antimicrob Agents Chemother; 2001 Jan; 45(1):312-5. PubMed ID: 11120986
    [TBL] [Abstract][Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.